Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Hepatocellular 121Carcinoma, Renal Cell 60Neoplasms 43Liver Neoplasms 42Neoplasm Metastasis 23Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 20Melanoma 18Kidney Neoplasms 16Breast Neoplasms 16Brain Neoplasms 13Pancreatic Neoplasms 12Sarcoma 11Prostatic Neoplasms 10Glioblastoma 10Lung Neoplasms 9Thyroid Neoplasms 8Recurrence 8Rectal Neoplasms 8Colorectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Colonic Neoplasms 7Stomach Neoplasms 6Ovarian Neoplasms 6Multiple Myeloma 6Leukemia 6Gliosarcoma 6Carcinoma 6Unspecified Adult Solid Tumor, Protocol Specific 5Urinary Bladder Neoplasms 4

Interventions

pirfenidone 3trametinib 1tipifarnib 1peginterferon alfa-2b 1nilotinib 1dabrafenib 1cabozantinib 1binimetinib 1Vinblastine 1Surveys and Questionnaires 1Sorafenib 1Pharmacokinetics 1Methotrexate 1Acceptance and Commitment Therapy 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neurofibroma, Plexiform × Sorafenib × Clear all
NCT00727233 2019-12-12

Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
9 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡